FDA approves first treatment for thyroid eye disease

A treatment for thyroid eye disease has been approved by the US Food and Drug Administration (FDA) for the first time.

The approved drug, Tepezza (teprotumumab-trbw), is manufactured by Horizon Therapeutics Ireland and has been approved for adults living with the rare eye disease.

Wiley Chambers, deputy director of the Division of Transplant and Ophthalmology Products at the FDA’s Centre for Drug Evaluation and Research, said: ‘Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non-surgical treatment option.’